Attenuation of doxorubicin-induced cardiac injury by mitochondrial glutaredoxin 2  by Diotte, Nicole M. et al.
Biochimica et Biophysica Acta 1793 (2009) 427–438
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbamcrAttenuation of doxorubicin-induced cardiac injury by mitochondrial glutaredoxin 2☆
Nicole M. Diotte a, Ye Xiong a, Jinping Gao b, Balvin H.L. Chua b, Ye-Shih Ho a,⁎
a Institute of Environmental Health Sciences and Department of Biochemistry and Molecular Biology, Wayne State University, 2727 Second Avenue, Room 4000, Detroit, MI 48201, USA
b Department of Pharmacology and Cecile Cox Quillen Laboratory of Geriatric Research, James H. Quillen College of Medicine, East Tennessee State University; and James H. Quillen Veterans
Affairs Medical Center, Johnson City, TN, USAAbbreviations: DOX, doxorubicin; ROS, reactive oxyg
protein–SSG, protein–glutathione mixed disulﬁdes; G
glutaredoxin Trx1, thioredoxin 1, Trx2, thioredoxin 2;
P/O ratio, ADP/O ratio; CuZnSOD, copper–zinc sup
manganese superoxide dismutase; Gpx1, glutathione per
heavy chain; BCA, bicinchoninic acid; HED, 2-h
N-ethylmaleimide
☆ The work was supported by American Heart Associa
grants 0455876Z and 0655631Z, and a pilot grant from N
Y.-S. H.; and by NIH grant HL087271, a grant from the D
Merit Review, and a grant-in-aid from American Heart As
B.H.L.C. The use of equipment in the Imagine and Cytome
by a Center grant P30 ES06639.
⁎ Corresponding author. Tel.: +1 313 963 7660; fax: +
E-mail address: yho@wayne.edu (Y.-S. Ho).
0167-4889/$ – see front matter © 2008 Elsevier B.V. Al
doi:10.1016/j.bbamcr.2008.10.014a b s t r a c ta r t i c l e i n f oArticle history: While the cardiotoxicity of
Received 29 August 2008
Received in revised form 24 October 2008
Accepted 24 October 2008
Available online 6 November 2008
Keywords:
Oxidative stress
Protein S-glutathionylation
Transgenic mice
Mitochondria
Cytochrome cdoxorubicin (DOX) is known to be partly mediated through the generation of
reactive oxygen species (ROS), the biochemical mechanisms by which ROS damage cardiomyocytes remain to
be determined. This study investigates whether S-glutathionylation of mitochondrial proteins plays a role in
DOX-induced myocardial injury using a line of transgenic mice expressing the human mitochondrial
glutaredoxin 2 (Glrx2), a thiotransferase catalyzing the reduction as well as formation of protein–glutathione
mixed disulﬁdes, in cardiomyocytes. The total glutaredoxin (Glrx) activity was increased by 76% and 53 fold
in homogenates of whole heart and isolated heart mitochondria of Glrx2 transgenic mice, respectively,
compared to those of nontransgenic mice. The expression of other antioxidant enzymes, with the exception
of glutaredoxin 1, was unaltered. Overexpression of Glrx2 completely prevents DOX-induced decreases in
NAD- and FAD-linked state 3 respiration and respiratory control ratio (RCR) in heart mitochondria at days 1
and 5 of treatment. The extent of DOX-induced decline in left ventricular function and release of creatine
kinase into circulation at day 5 of treatment was also greatly attenuated in Glrx2 transgenic mice. Further
studies revealed that heart mitochondria overexpressing Glrx2 released less cytochrome c than did controls
in response to treatment with tBid or a peptide encompassing the BH3 domain of Bid. Development of
tolerance to DOX toxicity in transgenic mice is also associated with an increase in protein S-glutathionylation
in heart mitochondria. Taken together, these results imply that S-glutathionylation of heart mitochondrial
proteins plays a role in preventing DOX-induced cardiac injury.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
The anthracycline antibiotic doxorubicin (DOX) is one of the most
effective anticancer drugs for treating various types of cancers such as
carcinomas, soft tissue sarcomas, multiple myeloma, non-Hodgkin's
lymphomas, and Hodgkin's disease. However, the therapeutic effec-
tiveness of DOX is greatly restricted by its dose dependent and
cumulative cardiotoxic side effects [1–4].en species; GSH, glutathione;
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l rights reserved.Themechanism bywhich DOX causesmyocardial injury is not fully
understood. Nonetheless, the free radical hypothesis of DOX toxicity
has been steadily gaining support over the years. Following entry into
cardiomyocytes, DOX can generate reactive oxygen species (ROS) via
two distinct mechanisms. First, it can form a complex with iron(III).
The iron subsequently receives one electron from the bounded DOX to
generate an iron(II)-DOX free radical complex which can then reduce
oxygen and hydrogen peroxide to superoxide anion radical (super-
oxide) and hydroxyl radical, respectively [5,6]. Second, DOX can also
generate ROS through the mechanism of reduction–oxidation (redox)
cycling, a reaction that is catalyzed by a number of NAD(P)H
oxidoreductases [7–12]. At the subcellular level, mitochondria are
believed to be the primary target of DOX-induced cardiotoxicity. The
mitochondria of DOX-poisoned heart show morphological abnormal-
ities that are associated with biochemical derangements including
inhibition of electron transfer complexes, decrease in efﬁciency of
respiration, and disruption of calcium homeostasis [13–19].
The role of ROS in DOX-induced cardiac toxicity is supported by
the ﬁndings that treatment of animals with a variety of antioxidants
such as probucol, amifostine, dexrazoxane, and melatonin protects
heart against the toxicity of DOX [20–24]. Furthermore, overexpres-
sion of antioxidant enzymes such as manganese superoxide
dismutase (MnSOD), catalase, or glutathione peroxidase 1 (Gpx1) in
Fig. 1. Characterization of the human Glrx2 transgenic mice. (A) Schematic diagram of the human Glrx2 transgene. The full-length human Glrx2 cDNA coding for the mitochondrial
Glrx2 was cloned downstream to a 5.5-kb mouse genomic fragment (namelyα-5.5) which spans from the last intron of the mouse β-MyHC gene to the 5′ untranslated region of exon
3 of the mouse α-MyHC gene. Open box represents the last noncoding exon of the mouse β-MyHC gene. Black boxes represent the ﬁrst three exons of the mouse α-MyHC gene. The
number of the exon of themouseα-MyHC gene is indicated under each exon. The locations of three unique restriction sites are also indicated in themap. CAP represents transcription
initiation site of the mouse α-MyHC gene. (B) RNA blot analysis showing expression of Glrx2 transgene in heart and lungs of a transgenic mouse. The RNA blot membrane was ﬁrst
hybridized with 32P-labeled human Glrx2 cDNA and then re-hybridized with a cDNA coding for the rat glyceraldehyde 3-phosphate dehydrogenase (Gapd) to determine the
variations in sample loading. (C) Protein blot analysis of tissue homogenates showing that the human Glrx2 protein is speciﬁcally expressed in heart of a transgenic mouse. To reveal
variations in sample loading, the same blot membrane was re-reacted with antibodies against copper–zinc superoxide dismutase (CuZnSOD). (D) Expression of the human Glrx2
protein in heart mitochondria of Glrx2 transgenic mice. Ten micrograms of heart mitochondrial proteins from 5 male nontransgenic mice and 6 male Glrx2 transgenic mice were
separated on a SDS-polyacrylamide gel for blot analysis. Another blot membrane prepared from a gel loaded with the same amounts of samples was reacted with antibodies against
manganese superoxide dismutase (MnSOD). (E) Total Glrx activity in whole heart homogenates and homogenates of isolated heart mitochondria of nontransgenic and littermate
Glrx2 transgenic mice. Each value represents mean±SD and n≥5. ⁎, pb0.0001 compared to the corresponding samples of nontransgenic mice. (F) Expression of antioxidant
enzymes in hearts of nontransgenic and Glrx2 transgenic mice. Thirty micrograms of whole heart homogenates of six individual nontransgenic mice and Glrx2 transgenic mice were
loaded on several gels for blot analysis. The gender is shown on top of the ﬁgure. Square and circle represent male and female mice, respectively. In (B), (C), (D), and (F), − and +
represent nontransgenic and Glrx2 transgenic mice, respectively.
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cardiac injury [25–27]. Since MnSOD speciﬁcally converts superoxide
to H2O2 and the other two enzymes decompose H2O2, these studies
strongly support the role of ROS in DOX-induced cardiotoxicity. In
addition, because MnSOD is only located in the mitochondria, the
results also indicate mitochondria as the major target of DOX-induced
toxicity in cardiomyocytes.Although these studies have demonstrated the role of ROS in DOX-
induced myocardial injury, the biochemical mechanisms by which
ROS damage cardiomyocytes are not understood. Previous studies
have shown that protein cysteinyl thiols are among the most
susceptible targets of ROS within cells. The cysteine residues of
proteins, in the absence of vicinal thiols, can be sequentially oxidized
to cysteine sulfenic acids (–SOH), sulﬁnic acids (RSO2H), and sulfonic
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thiols and non-protein thiols such as glutathione (GSH) to form intra-
and inter-protein disulﬁdes and protein–GSH mixed disulﬁdes
(protein–SSG), respectively. Since GSH is the most abundant non-
protein thiol in cells (at concentrations between 0.5 and 20 mM) [28],
the majority of protein mixed disulﬁdes formed inside cells under
oxidative stress is believed to be protein–SSG. S-glutathionylation can
have a profound effect on the catalytic and structural functions of
proteins. For example, the catalytic functions of transcription factors
NF-κB and NF-1 [29,30] protein tyrosine phosphatase 1B [PTP-1B]
[31,32], and protein kinase C-α [33] are inactivated by S-glutathiony-
lation. On the other hand, S-glutathionylation enhances the activities
of a number of other proteins, such as HIV-1 protease, glutathione S-
transferase, and Ras [34–36]. Therefore, the physiological changes due
to protein S-glutathionylation as a consequence of cell signaling
events or oxidative stress are dependent on which of the effector
proteins is S-glutathionylated.
In mammals, the protein–SSG mixed disulﬁdes are predominantly
reduced by isoforms of glutaredoxin (Glrx) via a monothiol mechan-
ism [37]. Glutaredoxin 1 (Glrx1) is a 12-kDa cytosolic protein [38].
Glutaredoxin 2 (Glrx2) is expressed from two alternatively spliced
mRNAs, resulting in translocation into either the mitochondria or the
nucleus [39,40]. Interestingly, Glrx is also capable of catalyzing S-
glutathionylation of proteins in the presence of a glutathione-thiyl
radical generating system [41–43]. Further studies have shown that
overexpression of either Glrx1 or Glrx2 protects cells against injury
resulting from oxidative stress [44–49]. However, which of the two
catalytic activities of Glrx1 and Glrx2 contributes to their protective
function in vitro in cultured cells remains to be determined.
Thepresent studyseeks todeterminewhetherS-glutathionylationof
mitochondrial proteins in heart plays a role in DOX-inducedmyocardial
injury using a line of transgenic mice overexpressing mitochondrial
Glrx2 in cardiomyocytes. Our results show that Glrx2 overexpression
greatly protects mouse heart from DOX-induced mitochondrial and
contractile dysfunction, and the protection is associated with an
increased S-glutathionylation of mitochondrial proteins.
2. Materials and methods
2.1. Generation of human Glrx2 transgenic mice
To construct the transgene, a full-length cDNA fragment coding for
the humanmitochondrial Glrx2 (IMAGE clone 512859, NCBI accession
#AA062724) was isolated from plasmid vector pSK (Stratagene, La
Jolla, CA) by digestion with enzymes BamHI and XhoI (the BamHI
restriction site is located in the multiple cloning sites of plasmid pSK)
and then cloned into the corresponding restriction sites in plasmid
pSL1180 (GE Healthcare, Amersham Biosciences Corp, Piscataway, NJ).
The human Glrx2 cDNA fragment was again isolated from plasmid
pSL1180 by digestion with enzymes SalI and XhoI (the SalI restriction
site is located in the multiple cloning sites of plasmid pSL1180) and
inserted into a previously constructed expression vector at the SalI
site, downstream to the 5′ ﬂanking sequence and promoter of the
mouseα-myosin heavy chain (α-MyHC) gene [50]. [The DNA fragment
containing the 5′ ﬂanking sequence and promoter of the mouse α-
MyHC gene, namely α-5.5, was originally provided by Dr. Jeff Robbins
of University of Cincinnati, Cincinnati, OH [51]. The entire expression
sequence (Fig. 1A), including the genomic sequence of the mouse α-
MyHC gene, the human Glrx2 cDNA, and the SV40 splice and
polyadenylation sites (Fig. 1A), was released from the expression
vector by digestion with enzymes ClaI and NotI and puriﬁed after
separation on an agarose gel. The DNA fragment was then micro-
injected into the pronuclei of fertilized eggs harvested from female
B6C3 (C57BL/6 × C3H) F1 mice mated with male B6C3 F1 mice
according to the standard method [52]. Only one line of transgenic
mice was generated. The mice used in the studies were generated bybreeding the female (hemizygous) transgenic mouse with male B6C3
hybrid mice. Transgenic mice were identiﬁed by Southern blot
analysis of mouse tail DNA. Both the male and female mice were
used in the studies and the nontransgenic littermates were used as
controls for transgenic mice.
2.2. Preparation of tissue samples for gene expression studies
Total RNA was isolated from tissues of Glrx2 transgenic mouse and
nontransgenic littermate using the TRIZOL reagent (Invitrogen,
Carlsbad, CA) according to the procedures recommended by the
manufacturer. Thirty micrograms of total RNA were denatured with
glyoxyal and subjected to blot analysis according the method
described by Thomas [53]. For protein analysis, tissues were
homogenized in 1.5 to 2 ml of lysis buffer (50 mM potassium
phosphate buffer, pH 7.8, 0.5% Triton X-100, and 3% glycerol)
containing protease inhibitor cocktail (P-8340, Sigma, St. Louis, MO)
and 1 mM phenylmethylsulfonyl ﬂuoride with a Polytron homo-
genizer, followed by sonication. The homogenates were then clariﬁed
by centrifugation at 20,000 ×g for 15 min and stored at −70 °C. The
protein concentration of tissue homogenates was determined by the
use of a bicinchoninic acid (BCA) protein assay kit (Pierce, Rockford,
IL). Thirty micrograms of tissue proteins were separated on a SDS-
polyacrylamide gel for blot analysis. The protein blot membrane was
reactedwith polyclonal antibodies against the humanGlrx2 generated
in rabbits (kindly provided by Dr. Marjorie Lou of University of
Nebraska at Lincoln, Lincoln, NE), and with antibodies against human
copper–zinc superoxide dismutase (CuZnSOD), rat manganese super-
oxide dismutase (MnSOD), bovine catalase, human Glrx1, and human
thioredoxin 2 (Trx2), followed by the standard procedures of
chemiluminescence to visualize the antibody-bound proteins on an
X-ray ﬁlm. The intensities of the signals were quantiﬁed using a Kodak
Imagine Station 440CF equipped with the Kodak ID Image Analysis
Software (Eastman Kodak Company, Rochester, NY).
2.3. Enzymatic activity assay for Glrx
The method described by Johansson et al. [54] was used to
determine the total activity of Glrx (including Glrx1 and Glrx2) in
homogenates of mouse hearts and isolated heart mitochondria. Brieﬂy,
10 μl of 70mM2-hydroxyethyl disulﬁde (HED)were added to 0.96ml of
reaction mixture containing 100 mM Tris–HCl, pH 8.0, 2 mM EDTA,
0.1 mg/ml bovine serum albumin, 200 μM NADPH, 1 mM GSH, and 0.4
U/ml of glutathione reductase, followedby incubation at 30 °C for 3min.
Fifty microliters of diluted heart or mitochondrial homogenate were
then added to the reactionmixture to initiate the reaction. The decrease
in absorbance at 340 nmwas then followed for 30 s using a Shimadzu
UV-160U spectrophotometer (Shimadzu Inc., Columbia, MD). The
background rates of NADPH oxidation resulting from sample alone
(without HED) and HED alone (without sample) were also measured
and deducted from the observed decrease of absorbance at 340 nm. The
amount of NADPH oxidation in the reaction was calculated using an
extinction coefﬁcient of 6.2mM−1cm−1. The activity of Glrx is deﬁned as
nmoles (nmol) of NADPH oxidized in 1 min by 1 mg of protein.
2.4. Enzymatic activity assay for glutathione peroxidase and thioredoxin
reductase-dependent peroxidase
The glutathione peroxidase activity was measured in a reaction
coupled to NADPH oxidation. Sodium azide was added to the reaction
mixture to inhibit the activity of catalase [55]. Brieﬂy, 0.1ml of heart or
mitochondrial homogenate were initially mixed with 0.85 ml of
reaction mixture (20 mM potassium phosphate buffer, pH 7.0, 0.6 mM
EDTA, 0.15 mMNADPH, 2 mMGSH, 1 mM sodium azide, and 4 U/ml of
glutathione reductase) at room temperature. The reaction was then
initiated by adding 50 μl of 2 mM hydrogen peroxide to the reaction
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30 s. The activity of glutathione peroxidase was deﬁned as nmoles
(nmol) of NADPH oxidized in 1 min by 1 mg of protein at 2 mM GSH.
The thioredoxin-dependent peroxidase activity was measured in a
solution of 50 mM Hepes (pH 7.3), 0.12 μM recombinant rat
thioredoxin reductase (American Diagnostica Inc, Stamford, CT), and
0.2 mM NADPH [56]. The reaction was initiated by addition of H2O2 to
a ﬁnal concentration of 0.25 mM, and the decrease in absorbance at
340 mm was then followed.
2.5. Treatment of mice with doxorubicin
Mice of either sex at 8 to 10 weeks of age were injected
intraperitoneally with DOX (EMD Biosciences, Inc., La Jolla, CA)
dissolved in normal saline at a dose of 22.5 mg/kg or saline alone as
control. Themicewere thensacriﬁcedatbothdays1and5post injection
for determining the efﬁciencyof respiration of heartmitochondria, or at
day 5 only for measurement of cardiac contractile function in vivo.
2.6. Isolation of mouse heart mitochondria and measurement of
mitochondrial respiratory and phosphorylating activities
Mouse heart mitochondria were isolated and their respiratory and
phosphorylating activities measured according to the methods
described previously [27]. The purity of mitochondria was evaluated
by protein blot analysis using antibodies against lamin B, cytochrome
P450 CYP1A1/2, and heat shock protein Hsp90α, the proteins that are
present in the nuclei, microsomes, and cytosol, respectively. None of
these antibodies reacted with the proteins prepared from the isolated
heart mitochondria (data not shown). Respiratory control ratio (RCR)
wascalculatedas the ratioof state3 to state4 respiration.ADP/Oratio (P/
O ratio)was determined by dividing the amount (nmoles) of ADP added
by the amount (natoms) of oxygen consumedduring state 3 respiration.
2.7. Activity assay for creatine kinase in serum
Mouse blood was collected by cardiac puncture at the time of
sacriﬁce. The blood was then placed in a microfuge tube and allowed
to fully clot on ice for 30 min. The tube was then centrifuged to
separate serum from the clot and cell pellet. The activity of creatine
kinase in serum was assayed using two commercial kits (Sigma, S.
Louis, MO and Diagnostic Chemicals Limited, Charlottetown, PE,
Canada) according to the procedures suggested by the manufacturers.
2.8. Measurement of in vivo cardiac function
At day 5 of saline or DOX treatment, mice were anesthetized with
2% isoﬂurane and ventilated with room air (at a tidal volume of 0.5 ml
and a rate of 110–120 breaths/min) through a tracheostomy cannula
that was connected to a rodent respirator (Columbus Instruments
International, Columbus, OH). A substernal transverse incision was
then made to expose the heart and the inferior vena cava. A microtip
pressure–volume catheter (SPR-839; Millar Instruments, Houston, TX)
was inserted into the left ventricle through a 25-gauge apical stab
wound to allow measurement of the steady state cardiac function. To
acutely change the cardiac preload, occlusion of inferior vena cavawas
produced over a 1-s period. At the completion of study, 10 μl of
hypertonic saline (15%) were injected into the right atrium to allow
calibration of the parallel volume (Vp). The conductance and pressure
signals were continuously recorded at a sampling rate of 1000 s−1
using an ARIA pressure–volume conductance system (Millar Instru-
ments) that was coupled to a Powerlab/4SP A/D converter (AD
Instruments, Mountain View, CA), and then stored and displayed on a
computer. Data were recorded as a series of pressure–volume loops
and analyzed with a cardiac pressure–volume analysis program
(PVAN3.4; Millar Instruments, Houston, TX).2.9. Induction of cytochrome c release from isolated heart mitochondria
Release of cytochrome c from heart mitochondria was induced
with either a 26-mer peptide containing the BH3 domain of Bid
(EDIIRNIARHLAQVGDSMDRSIPPGL) or recombinant mouse tBid
(Sigma, St. Louis, MO). Brieﬂy, heart mitochondria of nontransgenic
and Glrx2 transgenic mice (containing 0.1 mg of protein) were
incubated at 37 °C in 60 μl of experimental buffer (125 mM KCL,
10 mM Tris–MOPS, pH 7.4, 1 mM KH2PO4, 5 mM glutamate, 2.5 mM
malate, and 10 μM EGTA) as control, or in the same buffer
supplemented with a 26-mer peptide encompassing the BH3 domain
of Bid (at a ﬁnal concentration of 50 μM) or a recombinant mouse tBid
(at a ﬁnal concentration of 1 μM). At 0, 0.5, 1, and 2 h of incubation, a
set of tubes was removed from the water bath and the mitochondria
were separated by centrifugation at 15,000 ×g for 5 min. The
supernatant in each tube was collected and stored under −20 °C
until further study. The pellet of mitochondriawas dissolved in 75 μl of
solution containing 10 mM Tris, pH 8.0, 1 mM EDTA, and 1% SDS. The
content of cytochrome c in these samples was determined by protein
blot analysis using a rabbit monoclonal antibody purchased from Cell
Signaling Technologies Corp. (Danvers, MA).
2.10. Detection of protein S-glutathionylation in heart mitochondria by
protein blot analysis
For determining the effect of Glrx2 overexpression on S-glutathio-
nylation of mitochondria proteins, the minced mouse heart in 3.0 ml
of SEE solution (250 mM sucrose, 10 mMHepes, pH 7.4, 0.5 mM EGTA,
0.5 mM EDTA, and 1.0 mg/ml defatted BSA) containing Nagarse (5 mg/
g tissue) was initially subjected to a total of four cycles of
homogenization as described previously [27]. The total volume of
the heart homogenate was then adjusted to 10 ml with SEE solution
containing 30 mM N-ethylmaleimide (NEM) to prevent further S-
glutathionylation of proteins during sample manipulation. The same
concentration of NEM was also included in the SEE and sucrose
solutions that were used in the subsequent washing procedures for
isolation of mitochondria. Finally, the pellet of heart mitochondriawas
re-suspended in 0.3 ml of lysis buffer, as that used for preparation of
whole heart homogenate, containing 30 mM NEM, and stored at
−70 °C. The suspension of heart mitochondria was then subjected to
two cycles of freezing-and-thawing and clariﬁed by centrifugation at
20,000 ×g for 15 min. The supernatant was collected and protein
concentration determined by the BCA method. Forty micrograms of
soluble proteins of heart mitochondria were then separated on a non-
reducing SDS-polyacrylamide gel and transferred to a piece of
nitrocellulose membrane. The protein blot membrane was reacted
with a monoclonal antibody against GSH (ViroGen, Watertown, MA).
2.11. Statistical analysis
For experiments containing more than two groups of samples, the
data were ﬁrst analyzed by one-way analysis of variance (ANOVA),
followed by a Newman–Keuls post hoc comparison. The unpaired t
test was used to analyze the experiments consisting of only two
groups of samples. Differences with a p valueb0.05 are considered
statistically signiﬁcant.
3. Results
3.1. Generation and characterization of transgenic mice overexpressing
Glrx2 in mitochondria of cardiomyocytes
To investigate whether the mitochondrial Glrx2 functions in
preventing DOX-induced cardiotoxicity, we generated a line of
transgenic mice in which the human Glrx2 transgene is driven by
the 5′ ﬂanking sequence and promoter of the mouse α-MyHC gene
Fig. 2. Glrx2 overexpression prevents DOX-induced decrease in the efﬁciency of NAD-linked respiration in heart mitochondria at 1 day of treatment. (A) DOX treatment decreases the
rate of state 3 respiration in heart mitochondria of nontransgenic mice but not Glrx2 transgenic mice. (B) The rate of state 4 respiration is not affected by DOX treatment in either
nontransgenic or Glrx2 transgenic mice. (C) The efﬁciency of NAD-linked oxidative phosphorylation (as determined by the value of RCR) is decreased in heart mitochondria of
nontransgenic mice but not littermate Glrx2 transgenic mice. (D) The P/O ratio of NAD-linked respiration is not affected by DOX treatment in heart mitochondria of either type of
mice. Each bar represents mean±SD and n=6 for each experiment. ⁎, pb0.05 and #, pb0.001 versus heart mitochondria of saline-treated nontransgenic mice.
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found to be highly expressed in heart and to a much lesser extent in
lungs of a transgenic mouse (Fig. 1B). Expression of the human Glrx2
protein in hearts of transgenic mice was demonstrated by protein blot
analysis using an antiserum against human Glrx2 that has a very low
afﬁnity for the endogenous mouse Glrx2 protein (Fig. 1C). However,
the human Glrx2 protein in lungs of transgenic mice was not
detectable due to the very low level of mRNA expressed.
Since the human Glrx2 cDNA contained in the transgene codes for
a mitochondrial Glrx2 protein, expression of the human Glrx2 protein
in heart mitochondria of transgenic mice was further conﬁrmed by
protein blot analysis (Fig. 1D). These ﬁndings suggest that the human
Glrx2 protein is properly translocated into the mitochondria of
transgenic hearts.
We then determined whether the expressed human Glrx2 is
functional. As shown in Fig. 1E, the total Glrx activity in whole heart
homogenates of transgenic mice was increased by 76% compared to
that of nontransgenic mice. Since this study measured the activities of
bothGlrx1 andGlrx2, the result did not reﬂect the net increase of Glrx2
activity in heart mitochondria. To further understand the extent of
Glrx2 overexpression in heart of transgenic mice, total Glrx activity in
homogenates of isolated heart mitochondria was determined. As
shown in Fig. 1E, Glrx activity in heart mitochondria of nontransgenic
mice was barely detectable (1.44±0.74 nmol NADPH/min/mg protein),
andexpressionof thehumanGlrx2 transgene in cardiomyocytes leaded
toa53 fold increase inGlrx activity (77.68±23.51nmolNADPH/min/mg
protein) in heart mitochondria of Glrx2 transgenic mice.
Finally, we determined whether an increase in Glrx2 activity in
heart of transgenic mice affects the expression of other antioxidant
enzymes. As shown in Fig. 1F, the protein levels of CuZnSOD, MnSOD,
catalase, and Trx2 were unchanged in hearts of Glrx2 transgenic micecompared to those of their nontransgenic littermates. Furthermore,
the activities of glutathione peroxidase were equivalent in whole
heart homogenates of nontransgenic and Glrx2 transgenic mice
(9.46±0.97 vs. 8.69±0.92 nmol NADPH/min/mg protein, respectively;
p=0.185, n=6). However, the protein level of Glrx1 was increased by
109% (pb0.001) in heart of Glrx2 transgenic mice relative to that of
nontransgenic littermates (Fig. 1F). Finally, because all the antibodies
commercially available only react with the human thioredoxin 1
(Trx1) but not the corresponding mouse protein, we were not able to
measure it level of expression in mouse heart.
3.2. Overexpression of Glrx2 protects mouse heart against DOX-induced
mitochondrial dysfunction
Mitochondrion is the major subcellular organelle for generation of
ROS in DOX-poisoned hearts and therefore a direct target of oxidative
stress [7–9,13–19]. To investigate the effect of Glrx2 overexpression on
DOX-induced cardiac toxicity, we measured the efﬁciency of mito-
chondrial respiration in mouse hearts isolated from nontransgenic
and Glrx2 transgenic mice at days 1 and 5 of treatment with saline (as
control) or DOX. As shown in Figs. 2 through 4, the baseline values of
mitochondrial respiration including the rates of state 3 and 4
respiration, RCR, and P/O ratio using either NAD- or FAD-linked
substrates were equivalent in saline-treated nontransgenic and Glrx2
transgenic mice, indicating that overexpression of Glrx2 has no effect
on the efﬁciency of mitochondrial respiration in mouse heart under
normal physiological conditions.
However, at one day after DOX treatment, the rate of NAD-linked
state 3 respiration but not state 4 respiration was decreased by 36% in
heart mitochondria of nontransgenic mice compared to those of
saline-treated counterparts (Fig. 2A and B), leading to a 31% decrease
Fig. 3. Glrx2 overexpression attenuates DOX-induced decrease in the efﬁciency of NAD-linked respiration in heart mitochondria at day 5 of treatment. In (A) and (C), DOX treatment
greatly decreases the rate of state 3 respiration and RCR in heart mitochondria of nontransgenic mice but not littermate Glrx2 transgenic mice. (B) The rate of state 4 respiration is not
changed following DOX treatment in either type of mice. (D) Glrx2 overexpression does not attenuate DOX-induced decrease in P/O ratio. Each bar represents mean±SD and n=6 for
each experiment. ⁎⁎pb0.01, and #, pb0.001 versus heart mitochondria of saline-treated mice with of the same genotype.
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using NAD-linked substrates in heart mitochondria of nontransgenic
mice is retarded due to DOX treatment. Remarkably, overexpression of
mitochondrial Glrx2 completely prevented the functional abnormal-
ities of heart mitochondria as a result of DOX treatment (Fig. 2A and C).
On the other hand, the P/O ratio of all mitochondrial samples was not
affected by DOX at day 1 of treatment (Fig. 2D), suggesting that the
mitochondrial electron transport chain is still tightly coupled to
oxidative phosphorylation. Furthermore, DOX treatment had no effect
on FAD-linked respiration in heart mitochondria of either nontrans-
genic or Glrx2 transgenic mice (data not shown).
DOX had a more profound impact on mitochondrial respiration at
day 5 of treatment. As shown in Fig. 3A and C, heart mitochondria of
nontransgenic mice exhibited 65% and 66% decreases in NAD-linked
state 3 respiration and RCR, respectively, compared to saline-treated
counterparts. Again, these functional derangements of mitochondria
could be completely prevented by Glrx2 overexpression (Fig. 3A and
C). In addition, the P/O ratio of heart mitochondria from DOX-treated
nontransgenic mice was decreased by 19% relative to the control level
(Fig. 3D). Since the rate of state 4 respiration is not altered by DOX
treatment (Fig. 3B), a decrease in P/O ratio suggests that electron
transport in the respiratory chain is partially uncoupled from
oxidative phosphorylation. To our surprise, this defect was not
preventable by Glrx2 overexpression (Fig. 3D).
While DOX at day 1 of treatment did not affect FAD-linked
respiration in heart mitochondria of either type of mice, it did at day 5
of treatment. As shown in Fig. 4A through C, while the rate of FAD-
linked state 4 respiration remained unchanged in DOX-treated
nontransgenic mice, the rate of state 3 respiration was decreased by
27% compared to that of controls, resulting in a 19% decrease in RCR.
The observed declines in mitochondrial respiration could also becompletely prevented by overexpression of Glrx2 in transgenic hearts.
DOX treatment also caused a decrease in P/O ratio of heart
mitochondria isolated from either type of mice (Fig. 4D). Although
the magnitude of decrease in heart mitochondria of Glrx2 transgenic
mice is less than that of nontransgenic mice (14% vs. 27%,
respectively), the difference is not statistically signiﬁcant, suggesting
that an enhanced expression of Glrx2 is not capable of ameliorating
DOX-induced uncoupling of the electron transport chain in mitochon-
drial respiration that uses FAD-linked substrate.
3.3. Glrx2 overespression prevents DOX-induced release of creatine
kinase from heart into circulation
Elevated level of creatine kinase in serum has been used as a
marker for determining the extent of heart injury in mice treated with
DOX [25,26]. As shown in Fig. 5A, the serum level of creatine kinase
was not changed in both types of mice at day 1 of DOX treatment.
However, at day 5 of DOX treatment, therewas an approximately 500%
increase in the level of serum creatine kinase in nontransgenic mice
but not in Glrx 2 transgenic mice compared to their saline-treated
counterparts (Fig. 5B). These data support the role of Glrx2 in
cardioprotection against DOX toxicity. Furthermore, since Glrx2 is
speciﬁcally overexpressed in hearts of transgenic mice, our results
indicate that heart is themajor organ that releases creatine kinase into
the circulation due to DOX toxicity.
3.4. Glrx2 overespression prevents DOX-induced decline in left
ventricular function
We next determined whether overexpression of Glrx2 also
protects mouse heart from DOX-induced decline in left ventricular
Fig. 4. Glrx2 overexpression attenuates DOX-induced decrease in the efﬁciency of FAD-linked respiration in heart mitochondria at day 5 of treatment. In (A) and (C), FAD-linked state
3 respiration and RCR are decreased in heart mitochondria of nontransgenic mice but not littermate Glrx2 transgenic mice treated with DOX. (B) The rate of state 4 respiration is not
affected by DOX treatment in either type of mice. (D) Glrx2 overexpression does not attenuate DOX-induced decrease in P/O ratio. Each bar represents mean±SD and n=6 for each
experiment. ⁎pb0.05, ⁎⁎pb0.01, and # pb0.001 versus heart mitochondria of saline-treated mice of the same genotype.
433N.M. Diotte et al. / Biochimica et Biophysica Acta 1793 (2009) 427–438function. Previous studies have shown that the contractile function
of mouse heart is not affected at one day after DOX treatment
(data not shown). We therefore measured the in vivo cardiac
function of nontransgenic and Glrx2 transgenic mice at 5 days after
DOX treatment. As shown in Table 1, there were no differences in
the body weight and cardiac function between nontransgenic and
Glrx2 transgenic mice receiving treatment of saline, indicating
that overexpression of mitochondrial Glrx2 has no effect on the
basal hemodynamic indices of mouse heart. However, the left
ventricular contractile function was signiﬁcantly depressed in DOX-Fig. 5. Glrx2 overexpression prevents DOX-induced increase in serum creatine kinase at day
treatment with saline or DOX and serum was then prepared. Each bar represents mean±SDtreated nontransgenic mice, as evidenced by a signiﬁcant decrease
in heart rate (29%), stroke index (SI) (36%), cardiac index (CI) (52%),
ejection fraction (EF) (43%) and preload recruitable stroke work
(PRSW) (61%) in comparison to those of saline-treated nontrans-
genic mice. DOX treatment also caused alterations in systolic
function of nontransgenic hearts, including decreases in both end-
systolic pressure (Pes) and the maximal rate of pressure increasing
(dP/dtmax) and an increase in end-systolic volume (Ves). The same
was true for diastolic function of nontransgenic hearts, as shown
by DOX-induced increases in end-diastolic pressure (Ped) and τ5 of treatment. Blood was collected from mice via cardiac puncture at days 1 and 5 of
and n≥5. #, pb0.001 versus saline-treated nontransgenic mice.
Table 1
In vivo cardiac function of nontransgenic and Glrx2 transgenic mice at day 5 of
treatment with either saline or DOX
Parameter Nontransgenic mice Glrx2 Transgenic mice
Treatment Treatment
Saline DOX Saline DOX
Body weight (grams) 28.20±3.62 22.60±2.16⁎ 26.50±1.98 23.00±2.47‡
Heart rate (beats/min) 537±37 383±101⁎⁎ 537±51 487±47
SI (μl/g) 0.44±0.06 0.28±0.04⁎⁎ 0.47±0.06 0.40±0.06
CI (μl/g) 231±20 111±26⁎⁎ 250±37 194±29‡
EF (%) 69.40±2.06 39.40±6.56⁎⁎ 69.50±2.40 56.10±3.30‡
PRSW (mmHg) 97.10±14.27 37.90±13.70⁎⁎ 95.50±15.98 79.20±20.91
Systolic function
Pes (mmHg) 92.40±7.80 57.30±5.98⁎⁎ 93.00±5.53 82.30±10.95
Ves (μl) 5.74±0.44 10.24±1.84⁎⁎ 5.97±0.92 7.54±0.65‡
dP/dtmax (mmHg/s) 10714±1672 4861±1210⁎⁎ 9934±1404 9869±2611
dP/dtmax–Ved (mmHg/
μl)
764±217 302±133⁎⁎ 705±358 778±364
Diastolic function
Ped (mmHg) 3.82±0.34 5.16±0.93⁎⁎ 3.91±0.78 2.86±1.10
Ved (μl) 17.06±1.18 15.46±1.36⁎ 17.07±0.43 15.69±0.42‡
dP/dtmin (mmHg/s) 10899±1857 3772±922⁎⁎ 10911±1268 8814±931‡
τ (Weiss) (ms) 5.67±0.55 10.15±2.67⁎⁎ 5.80±0.61 6.34±0.76
β(beta) (mmHg/μl) 0.32±0.07 0.35±0.22 0.36±0.18 0.28±0.22
Vascular function
Ea (mmHg/μl) 7.43±0.70 9.35±1.45⁎ 7.65±0.69 9.11±1.14‡
SI, stroke index (SI=stroke volume/body weight); CI, cardiac index (CI=cardiac output/
body weight); EF, ejection fraction; PRSW, preload recruitable stroke work; Pes, end-
systolic pressure; Ves, end-systolic volume; dP/dtmax, the maximal rate of pressure
increasing; dP/dtmax–Ved, slope describing isovolumic contraction; Ped, end-diastolic
pressure; Ved, end-diastolic volume; dP/dtmin, the maximal rate of pressure
decreasing; τ (Weiss), time constant of isovolumic relaxation; β, slope of end-
diastolic pressure–volume relationship; Ea, arterial elastance. Each value represents
mean±SD of 6 hearts. ⁎, pb0.05 versus saline-treated nontransgenic mice and saline-
treated Glrx2 transgenic mice; ⁎⁎, pb0.05 versus saline-treated nontransgenic mice
and Glrx2 transgenic mice treated with either saline or DOX; ‡, pb0.05 versus saline-
treated Glrx2 transgenic mice.
Fig. 6. Attenuation of tBid-induced cytochrome c release from heart mitochondria by
Glrx2. (A) Representative protein blot analysis (from a total of four independent
experiments) of cytochrome c in pellets and supernatants of heart mitochondria of a
nontransgenic mouse and a Glrx2 transgenic littermate in the absence or presence of
50 μM BH3 peptide of Bid. (B) Representative protein blot study showing that heart
mitochondria from a Glrx2 transgenic mouse release less cytochrome c than do heart
mitochondria of a nontransgenic littermate following incubation with 1 μM of
recombinant mouse tBid.
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end-diastolic volume (Ved) and the maximal rate of pressure
decreasing (dP/dtmin).
Overexpression of mitochondrial Glrx2 in the heart completely
prevented DOX-induced changes in many hemodynamic parameters
including heart rate, SI, PRSW, systolic function (Pes and dP/dtmax), and
diastolic function (Ped and τ); and greatly attenuated the alterations in
other functional measurements such as CI, EF, Ves of systolic function,
and dP/dtmin of diastolic function compared to those of DOX-treated
nontransgenic mice. These results demonstrate the function of
mitochondrial Glrx2 in protecting heart from DOX-induced contractile
dysfunction.
On the other hand, the decrease in end-diastolic volume (Ved)
due to DOX treatment was not preventable by Glrx2 overexpres-
sion. In addition, Glrx2 overexpression did not attenuate DOX-
induced loss of body weight, indicating that cardiac injury resulting
from DOX toxicity is not a cause of this phenotypic change. Finally,
the extent of increase in peripheral vascular resistance (or arterial
elastance, Ea) due to DOX treatment was also not affected by an
enhanced expression of Glrx2. This result is anticipated. Since
Glrx2 is only overexpressed in cardiomyocytes, it should not have
an effect on DOX-induced increase in peripheral vascular resistance.
3.5. Glrx2 overexpression attenuates cytochrome c release from heart
mitochondria in response to tBid
Having established the protective role of Glrx2 in DOX toxicity,
we intended to investigate the mechanisms by which mitochondrial
Glrx2 limits DOX-induced myocardial injury. DOX-induced cardio-
myopathy in vivo in mouse heart is partly mediated through
apoptosis, as evidenced by the appearance of the typical apoptotic
morphology in cardiomyocytes as well as a marked increase inapoptotic effectors such as activated caspase 3 and cytosolic
cytochrome c in DOX-poisoned hearts [18,57–59]. We therefore
determined whether overexpression of Glrx2 affected the release of
cytochrome c form heart mitochondria in response to iBid, the
proteolytically cleaved product of Bid functioning in promoting
apoptosis [60]. As shown in Fig. 6A, heart mitochondria could
maintain the integrity of their membranes in vitro even after 2 h
incubation in the experimental buffer (as evidenced by the absence
of cytochrome c release into supernatant). However, inclusion of
either a 26-mer synthetic peptide encompassing the BH3 domain of
Bid or a recombinant mouse tBid in the experimental buffer caused
an extensive release of cytochrome c from heart mitochondria of a
nontransgenic mouse, with levels plateauing at 1 h of incubation
(Fig. 6A and B). Remarkably, overexpression of Glrx2 in heart
mitochondria greatly attenuated the extent of cytochrome c release
in response to the same treatments.
3.6. Glrx2 overexpression enhances S-glutathionylation of heart
mitochondrial proteins
We next investigated the effect of Glrx2 overexpression on
protein S-glutathionylation in heart mitochondria, since Glrx can
catalyze both de-glutathionylation and S-glutathionylation of
proteins [37,42–44]. As shown in Fig. 7A, the extent of S-
glutathionylation of several mitochondrial proteins in Glrx2 trans-
genic hearts was increased compared to that of nontransgenic
hearts. It is worth noting that because the cysteine residues of
these mitochondrial proteins are S-glutathionylated and may also
be alkylated with NEM, the molecular masses of these proteins
cannot be estimated using gel electrophoresis in which the
commercially available protein markers, that have been reduced
with dithiothreitol, are used as standards. Further studies showed
that these mitochondrial proteins of nontransgenic hearts also
became more prominently S-glutathionylated at day 5 of DOX
treatment, to a level higher than that of saline-treated nontrans-
genic mice but below that found in saline-treated Glrx2 transgenic
mice (Fig. 7B). DOX treatment further enhanced the extent of
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genic mice compared to that of the same mice treated with saline.
4. Discussion
Generation of ROS by DOX via the formation of a complex with iron
(III) and by the redox cycling reaction in cardiomyocytes is believed to
initiate a cascade of oxidative chain reactions that eventually leads to
the observed acute and chronic cardiotoxicity of DOX. Since iron(III)
may be present in all cellular compartments and the enzymes
responsible for redox cycling of DOX are located in the cytosol and
several subcellular organelles of cardiomyocytes [7–12], ROS are likely
to be generated throughout the entire cardiomyocyte. Whether the
oxidants generated in each of the subcellular compartments con-
tribute equally to DOX-induced cardiac injury is not understood.
However, previous studies have suggested that mitochondria are both
the primary subcellular site for generation of ROS and target of
oxidative stress in DOX-poisoned hearts [7–9,16,17,19,25,61]. Since
mitochondria play a major role in maintenance of normal cell
metabolic function and in the control of apoptosis [62], a decrease
in mitochondrial function as a result of oxidative damage often leads
to cell injury and potentially cell death. This hypothesis is supported
by an earlier study that cardiac overexpression of MnSOD effectively
attenuates DOX-induced toxicity [25]. The current study further
supports the mitochondrial hypothesis of DOX-induced cardiotoxicity
by showing the protective function of anothermitochondrial protein—
Glrx2 which catalyzes both de-glutathionylation and S-glutathionyla-
tion of proteins.
Our studies show that despite a decrease in efﬁciency of
mitochondrial respiration at day 1 of DOX treatment in nontransgenicFig. 7. Glrx2 overexpression and DOX treatment increase S-glutathionylation of heart m
nontransgenic mice and Glrx2 transgenic mice under normal physiological conditions. Forty
the use of reducing agent (β-mercaptoethanol) for blot analysis using an anti-GSH antibody
mice and Glrx2 transgenic mice at day 5 of treatment with either saline or DOX. In (A and B)
S-glutathionylated proteins are indicated by arrows on the right. The positions where the red
same amounts of samples was stained with Coomassie Brilliant Blue to ensure equal loadingmice (Fig. 2), the left ventricular function of these mice remains
normal. Contractile dysfunction was only found at day 5 of DOX
treatment when structural damage, including formation of intracyto-
plasmic vacuoles, extensive cell apoptosis and necrosis, and disarray of
myoﬁlaments, was evident [4,15,18,25,57,58]. These understandings
suggest that derangement of mitochondrial respiration may serve as
an early marker for DOX-induced cardiotoxicity, prior to when
structural and contractile abnormalities are apparent. However,
whether mitochondrial dysfunction directly contributes to the other
pathological changes found in DOX-poisoned hearts remains to be
determined.
The present study indicates the role of Glrx2 in preventing DOX-
induced cardiac injury. How does Glrx2 protect heart from DOX
toxicity? There are two potential mechanisms. First, as shown in Fig.
1E, overexpression of Glrx2 also induces the expression of the
endogenous mouse Glrx1, the cytosolic isoform of Glrx, in the heart.
Therefore, it is possible that the observed protective function of Glrx2
is mediated through an enhanced expression of Glrx1. However, heart
mitochondria of Glrx1 transgenic mice with cardiac overexpresssion
of Glrx1 (N20 fold increase in Glrx1 protein) are not protected from
DOX-induced dysfunction, suggesting that Glrx1 plays a very limited
role in cardioprotection against DOX treatment ([63], Ho et al.,
unpublished data). Second, a recent study indicates that Glrx2 also
exhibits GSH-dependent as well as thioredoxin reductase-dependent
peroxidase activities [64]. This raises the possibility that the
cardioprotective function of Glrx2 may lie in its catalytic activity of
peroxidase but not de-glutathionylation/S-glutathionylation, since
overexpression of Gpx1 in mouse heart is known to attenuate the
cardiac toxicity of DOX [27]. We therefore measured the activity of
glutathione peroxidase (Gpx) in isolated heart mitochondria ofitochondrial proteins. (A) S-glutathionylation of mitochondrial proteins in hearts of
micrograms of soluble mitochondrial proteins were separated on a 11% SDS-gel without
. (B) Detection of S-glutathionylated mitochondrial proteins in hearts of nontransgenic
, square and circle represent male and female mice, respectively. The most prominently
uced protein standards migrate are indicated on the left. A duplicate gel loaded with the
of the samples (data not shown).
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former and latter samples are equivalent (13.63±3.72 vs. 14.14±
5.01 nmol NADPH/min/mg protein, respectively; p=0.83, n≥6),
suggesting that the contribution of the overexpressed Glrx2 to total
GSH-dependent peroxidase activity in heart mitochondria is negli-
gible, therefore excluding the Gpx activity of Glrx2 in cardioprotec-
tion. This result is not surprising since the catalytic efﬁciency of GSH-
dependent peroxidase of the human Glrx2 protein (2.5×104 s−1M−1) is
signiﬁcantly lower than that of Gpx (∼108 s−1M−1) [64]. Furthermore,
in contrast to the results of Fernando et al. [64], we failed to observe an
increase in thioredoxin reductase-dependent peroxidase activity in
heart mitochondria of Glrx2 transgenic mice compared to that of
nontransgenic mice (6.15±1.60 vs. 5.81±1.66 nmol NADPH/min/mg
protein, respectively; p=0.70, n≥6). These results rule out the roles of
the endogenous mouse Glrx1 as well as the associated peroxidase
activities of Glrx2 in preventing DOX-induced cardiac injury.
DOX treatment has been shown to induce apoptosis in vivo in
hearts of rodents as well as in vitro in cultured cardiomyocytes
[17,18,57–59]. However, whether death of cardiomyocytes by apopto-
sis directly contributes to DOX-inducedmyocardial injury and declines
in left ventricular function as observed in the experimental animals
and cancer patients is not known. Our studies show that heart
mitochondria overexpressing Glrx2 aremore resistant to tBid-induced
release of cytochrome c, an initiator of the post-mitochondrial
pathway of apoptosis via formation of an apoptosome with Apaf-1
(apoptotic protease activating factor 1) [65]. Although these results
suggest that the increased tolerance of heart mitochondria of Glrx2
transgenic mice to tBid-mediated apoptosis renders the mice more
resistant to DOX-induced cardiac toxicity, further studies to under-
stand the role of apoptosis in DOX-induced myocardial injury, such as
whether DOX treatment activates Bid in heart and whether Glrx2
modulates apoptosis in DOX-poisoned cardiomyocytes, are needed.
Glrx is known to play a major role in modulating the extent of
protein S-glutathionylation in mammalian cells by catalyzing
both the reduction and formation of protein–SSG mixed disulﬁdes.
The mechanism of Glrx-catalyzed protein S-glutathionylation is
not completely understood. However, it should be noted that the
S-glutathionylation activity of Glrx1 and Glrx2 has only been
demonstrated in vitro in reactions where puriﬁed proteins and
mitochondrial membrane are incubated with recombinant Glrx
proteins [42–44]. Whether this reaction also occurs in vivo is not
known. To date, overexpression of Glrx1 in cultured cells has always
been found to cause to an enhanced activity in removal of the
glutathionyl moiety in several proteins such as Ras, the inhibitory κB
kinase β (IKK-β), and procaspase 3 [36,66,67]; and down-regulation of
Glrx1 by RNA interference retards the rate of de-glutathionylation of
S-glutathionylated actin, procaspase 3, and IKK-β [66–68]. There is
only one study which provides indirect evidence to suggest that
Glrx1 promotes S-glutathionylation of the p65 subunit of NF-κB in
a line of pancreatic carcinoma cells exposed to both hypoxia and
N-acetyl-L-cysteine [69]. The current study for the ﬁrst time demon-
strates that an enhanced expression of Glrx2 increases S-glutathiony-
lation of heart mitochondrial proteins, and this is associated with
tolerance of heart to the toxicity of DOX. These results suggest that
S-glutathionylation of a limited number of heart mitochondrial
proteins plays a role in preventing DOX-induced mitochondrial dys-
function and the subsequent contractile abnormalities in heart. Future
studies to identify these S-glutathionylated mitochondrial proteins and
to determine the signiﬁcance of protein S-glutathionylation in the
cardioprotective function of Glrx2 should further our understanding in
the biochemical mechanisms of DOX-induced cardiac injury.
Finally, our studies implicate the role of Glrx2 in protecting the
mitochondrial electron transport chain from DOX-induced damage. As
shown in Figs. 2 through 4, the rate of NAD-linked but not FAD-linked
state 3 respiration is decreased in heart mitochondria of nontrans-
genic mice at one day after DOX treatment. Since the NAD-linkedrespiration is carried out by complexes I, III and IV of the electron
transport chain and FAD-linked respiration uses complexes II, III and
IV, the observed decline in NAD-linked respiration is believed to result
from impairment of complex I activity, as also documented in several
earlier studies [16,17,27,70]. In addition, DOX retards the rates of both
NAD- and FAD-linked state 3 respiration at day 5 of treatment,
suggesting that the activities of both complex I (for NAD-linked
respiration) and II (for FAD-linked respiration) are decreased, and/or
the activities of complexes III and/or IV are also affected. Most
importantly, the DOX-induced declines in rate of state 3 respiration
are completely absent in heart mitochondria of Glrx2 transgenic mice,
suggesting the function of Glrx2 in preventing DOX-induced inactiva-
tion of the mitochondrial electron transport chain.
In summary, our results show that overexpression of Glrx2 in heart
mitochondria signiﬁcantly prevents DOX-induced dysfunction of
mitochondrial respiration, release of creatine kinase from cardiomyo-
cytes into circulation, and decrease in left ventricular function.
Furthermore, the observed cardioprotective function of Glrx2 is
associated with an increase in S-glutathionylation of heart mitochon-
drial proteins, suggesting that formation of protein–SSG mixed
disulﬁdes is actually protective. The protection may result from the
altered catalytic/structural function of these S-glutathionylated
mitochondrial proteins. Alternatively, S-glutathionylation may pre-
vent a more drastic and irreversible modiﬁcation, such as formation of
sulﬁnic and sulfonic acids, of the cysteine residues in these proteins.
Further research to understand the molecular mechanisms of
cardioprotection by protein S-glutationylation should allow identiﬁ-
cation of new pathways of DOX-induced cardiotoxicity that can be
targeted therapeutically.
Acknowledgements
We are grateful to Dr. Jeff Robbins of University of Cincinnati for the
gift of the plasmid containing the 5′ ﬂanking sequence and promoter
of the mouse α-MyHC gene, Dr. Chuan-Pu Lee of Wayne State
University for lending us the equipment for measurement of
mitochondrial respiration, and Drs. David C. S. Huang and Ruth
Kluck of The Walter and Eliza Hall Institute of Medical Research,
Victoria, Australia, for the information regarding the use of the peptide
containing the BH3 domain of Bid.
References
[1] V.J. Ferrans, Overview of cardiac pathology in relation to anthracycline
cardiotoxicity, Cancer Treat. Rep. 62 (1978) 955–961.
[2] K. Shan, A.M. Lincoff, J.B. Young, Anthracycline-induced cardiotoxicity, Ann. Intern.
Med. 125 (1996) 47–58.
[3] M.R. Bristow, P.D. Thompson, R.P. Martin, J.W. Mason, M.E. Billingham, D.C.
Harrison, Early anthracycline cardiotoxicity, Am. J. Med. 65 (1978) 823–832.
[4] P.K. Singal, N. Iliskovic, Doxorubicin-induced cardiomyopathy, N. Engl. J. Med. 339
(1998) 900–905.
[5] J.L. Zweier, L. Gianni, J. Muindi, C.E. Myers, Differences in O2 reduction by the iron
complexes of adriamycin and daunomycin: the importance of the sidechain
hydroxyl group, Biochem. Biophys. Acta 884 (1986) 326–336.
[6] K.L. Malisza, B.B. Hasinoff, Production of hydroxyl radical by iron(III)-anthraqui-
none complexes through self-reduction and through reductive activation by the
xanthine oxidase/hypoxanthine system, Arch. Biochem. Biophys. 321 (1995)
51–60.
[7] J.H. Doroshow, Anthracycline antibiotic-stimulated superoxide, hydrogen per-
oxide, and hydroxyl radical production by NADH dehydrogenase, Cancer Res. 43
(1983) 4543–4551.
[8] K.J. Davies, J.H. Doroshow, Redox cycling of anthracyclines by cardiac mitochon-
dria. I. Anthracycline radical formation by NADH dehydrogenase, J. Biol. Chem. 261
(1986) 3060–3067.
[9] J.H. Doroshow, K.J. Davies, Redox cycling of anthracyclines by cardiac mitochon-
dria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical,
J. Biol. Chem. 261 (1986) 3068–3074.
[10] N.R. Bachur, S.L. Gordon, M.V. Gee, H. Kon, NADPH cytochrome P-450 reductase
activation of quinone anticancer agents to free radicals, Proc. Natl. Acad. Sci. U. S. A.
76 (1979) 954–957.
[11] J. Vásquez-Vivar, P. Martasek, N. Hogg, B.B.S. Masters, K.A. Pritchard, B.
Kalyanaraman, Endothelial nitric oxide synthase-dependent superoxide genera-
tion from Adriamycin, Biochemistry 36 (1997) 11293–11297.
437N.M. Diotte et al. / Biochimica et Biophysica Acta 1793 (2009) 427–438[12] A.P. Garner, M.J.I. Paine, I. Rodriguez-Crespo, E.C. Chinje, P.O. Oritz De Montellano,
I.J. Stratford, D.G. Tew, C.R. Wolf, Nitric oxide synthases catalyze the activation of
redox cycling and bioreductive anticancer agents, Cancer Res. 59 (1999)
1929–1934.
[13] M. Praet, G. Pollakis, E. Goormaghtigh, J.M. Ruysschaert, Damages of the
mitochondrial membrane in adriamycin treated mice, Cancer Lett. 25 (1984)
89–96.
[14] L.E. Solem, T.R. Henry, K.B. Wallace, Disruption of mitochondrial calcium
homeostasis following chronic doxorubicin administration, Toxicol. Appl. Phar-
macol. 129 (1994) 214–222.
[15] D.L. Santos, A.J. Moreno, R.L. Leino, M.K. Froberg, K.B. Wallace, Carvedilol protects
against doxorubicin-induced mitochondrial cardiomyopathy, Toxicol. Appl.
Pharmacol. 185 (2002) 218–227.
[16] K.B. Wallace, Doxorubicin-induced cardiac mitochondrionopathy, Pharmacol.
Toxicol. 93 (2003) 105–115.
[17] P.S. Green, C. Leeuwenburgh, Mitochondrial dysfunction is an early indicator of
doxorubicin-induced apoptosis, Biochim. Biophys. Acta 1588 (2002) 94–101.
[18] A. Ascensão, J. Magalhaes, J.M. Soares, R. Ferreira, M.J. Neuparth, F. Marques, P.J.
Oliveira, J.A. Duarte, Moderate endurance training prevents doxorubicin-induced
in vivomitochondriopathy and reduces the development of cardiac apoptosis, Am.
J. Physiol.: Heart Circ. Physiol. 289 (2005) H722–H731.
[19] P.J. Oliveira, M.S. Santos, K.B. Wallace, Doxorubicin-induced thiol-dependent
alteration of cardiac mitochondrial permeability transition and respiration,
Biochemistry (Mosc) 71 (2006) 194–199.
[20] X. Liu, Z. Chen, C.C. Chua, Y.S. Ma, G.A. Youngberg, R. Hamdy, B.H.L. Chua,
Melatonin as an effective protector against doxorubicin-induced cardiotoxicity,
Am. J. Physiol.: Heart Circ. Physiol. 283 (2002) H254–H263.
[21] N. Siveski-Iliskovic, N. Kaul, P.K. Singal, Probucol promotes endogenous antiox-
idants and provides protection against adriamycin-induced cardiomyopathy in
rats, Circulation 89 (1994) 2829–2835.
[22] C.F. Seifert, M.F. Nesser, D.F. Thompson, Dexrazoxane in the prevention of
doxorubicin-induced cardiotoxicity, Ann. Pharmacother. 28 (1994) 1063–1072.
[23] G.F. Samelis, G.P. Stathopoulos, D. Kotsarelis, I. Dontas, C. Frangia, P.E.
Karayannacos, Doxorubicin cardiotoxicity and serum lipid increase is prevented
by dexrazoxane (ICRF-187), Anticancer Res. 18 (1998) 3305–3309.
[24] P. Nazeyrollas, A. Prevost, N. Baccard, L. Manot, P. Devillier, H. Millart, Effects of
amifostine on perfused isolated rat heart and on acute doxorubicin-induced
cardiotoxicity, Cancer Chemother. Pharmacol. 43 (1999) 227–232.
[25] H.C. Yen, T.D. Oberley, S. Vichitbandha, Y.-S. Ho, D.K. Clair St, The protective role of
manganese superoxide dismutase against adriamycin-induced acute cardiac
toxicity in transgenic mice, J. Clin. Invest. 98 (1996) 1253–1260.
[26] Y.J. Kang, Y. Chen, P.N. Epstein, Suppression of doxorubicin cardiotoxicity by
overexpression of catalase in the heart of transgenic mice, J. Biol. Chem. 271 (1996)
12610–12616.
[27] Y. Xiong, X. Liu, C.P. Lee, B.H.L. Chua, Y.-S. Ho, Attenuation of doxorubicin-induced
contractile and mitochondrial dysfunction in mouse heart by cellular glutathione
peroxidase, Free Radical Biol. Med. 41 (2006) 46–55.
[28] A. Meister, M.E. Anderson, Glutathione, Annu. Rev. Biochem. 52 (1983) 711–760.
[29] E. Pineda-Molina, P. Klatt, J. Vazquez, A. Marina, M.G. de Lacoba, D. Perez-Sala, S.
Lamas, Glutathionylation of the p50 subunit of NF-κB: a mechanism for redox-
induced inhibition of DNA binding, Biochemistry 40 (2001) 14134–14142.
[30] S. Bandyopadhyay, D.W. Starke, J.J. Mieyal, R.M. Gronostajski, Thioltransferase
(glutaredoxin) reactivates the DNA-binding activity of oxidation-inactivated
nuclear factor I, J. Biol. Chem. 273 (1998) 392–397.
[31] W.C. Barrett, J.P. DeGnore, S. Konig, H.M. Fales, Y. Keng, Z. Zhong-Yin, M.B. Yim, P.B.
Chock, Regulation of PTP1B via glutathionylation of the active site cysteine 215,
Biochemistry 38 (1999) 6699–6705.
[32] W.C. Barrett, J.P. DeGnore, Y. Keng, Z. Zhang, M.B. Yim, P.B. Chock, Roles of
superoxide radical anion in signal transduction mediated by reversible regulation
of protein-tyrosine phosphatase 1B, J. Biol. Chem. 274 (1999) 34543–34546.
[33] N.E. Ward, J.R. Stewart, C.G. Ioannides, C.A. O, ' Brian, Oxidant-induced
S-glutathiolation inactivates protein kinase C-α (PKC-α): a potentialmechanism of
PKC isozyme regulation, Biochemistry 39 (2000) 10319–10329.
[34] D.A. Davis, F.M. Newcomb, D.W. Starke, D.E. Ott, J.J. Mieyal, R. Yarchoan,
Thioltransferase (glutaredoxin) is detected within HIV-1 and can regulate the
activity of glutathionylated HIV-1 protease in vitro, J. Biol. Chem. 272 (1997)
25935–25940.
[35] A.L. Dafre, H. Sies, T. Akerboom, Protein S-thiolation and regulation of microsomal
glutathione transferase activity by the glutathione redox couple, Arch. Biochem.
Biophys. 332 (1996) 288–294.
[36] T. Adachi, D.R. Pimentel, T. Heibeck, X. Hou, Y.L. Lee, B. Jiang, Y. Ido, R.A. Cohen,
S-glutathiolation of Ras mediates redox-sensitive signaling by angiotensin II in
vascular smooth muscle cells, J. Biol. Chem. 279 (2004) 29857–29862.
[37] Y. Yang, S. Jao, S. Nanduri, D.W. Starke, J.J. Mieyal, J. Qin, Reactivity of the human
thioltransferase (glutaredoxin) C7S, C25S, C78S, C82S mutant and NMR solution
structure of its glutathionyl mixed disulﬁde intermediate reﬂect catalytic
speciﬁcity, Biochemistry 37 (1998) 17145–17156.
[38] W.W. Wells, Y. Yang, T.L. Deits, Z.R. Gan, Thioltransferases, Adv. Enzymol. Relat.
Areas Mol. Biol. 66 (1993) 149–201.
[39] M. Lundberg, C. Johansson, J. Chandra, M. Enoksson, G. Jacobsson, J. Ljung, M.
Johansson, A. Holmgren, Cloning and expression of a novel human glutaredoxin
(Grx2) mitochondrial and nuclear isoforms, J. Biol. Chem. 276 (2001)
26269–26275.
[40] V.N. Gladyshev, A. Liu, S.V. Novoselov, K. Krysan, Q.A. Sun, V.M. Kryukov, G.V.
Kryukov, M.F. Lou, Identiﬁcation of a new mammalian glutaredoxin (thiotransfer-
ase), grx2, J. Biol. Chem. 276 (2001) 30374–30380.[41] S. Lind, R. Gerdes, I. Schuppe-Koistinen, I.A. Cotgreave, Studies on the mechanism
of oxidative modiﬁcation of human glyceraldehyde-3-phosphate dehydrogenase
by glutathione: catalysis by glutaredoxin, Biochem. Biophys. Res. Commun. 247
(1998) 481–486.
[42] D.W. Starke, P.B. Chock, J.J. Mieyal, Glutathione-thiyl radical scavenging
and transferase properties of human glutaredoxin (thioltransferase):
Potential role in redox signal transduction, J. Biol. Chem. 278 (2003)
14607–14613.
[43] S.M. Beer, E.R. Taylor, S.E. Brown, C.C. Dahm, N.J. Costa, M.J. Runswick, M.P.
Murphy, Glutaredoxin 2 catalyzes the reversible oxidation and glutathionyla-
tion of mitochondrial membrane thiol proteins: implications for mitochon-
drial redox regulation and antioxidant defense, J. Biol. Chem. 279 (2004)
47939–47951.
[44] E.B. Meyer, W.W. Wells, Thiotransferase increases resistance of MCF-7 cells to
adriamycin, Free Radical Biol. Med. 26 (1999) 770–776.
[45] C.A. Chrestensen, D.W. Starke, J.J. Mieyal, Acute cadmium exposure inactivates
thioltransferase (Glutaredoxin), inhibits intracellular reduction of protein-glu-
tathionyl-mixed disulﬁdes, and initiates apoptosis, J. Biol. Chem. 275 (2000)
26556–26565.
[46] D. Daily, A. Vlamis-Gardikas, D. Offen, L. Mittelman, E. Melamed, A. Holmgren, A.
Barzilai, Glutaredoxin protects cerebellar granule neurons from dopamine-
induced apoptosis by activating NF-κB via Ref-1, J. Biol. Chem. 276 (2001)
1335–1344.
[47] J.J. Song, J.G. Rhee, M. Suntharalingam, S.A. Walsh, D.R. Spitz, Y.L. Lee, Role of
glutaredoxin in metabolic oxidative stress. Glutaredoxin as a sensor of oxidative
stress mediated by H2O2, J. Biol. Chem. 277 (2002) 46566–46577.
[48] H. Murata, Y. Ihara, H. Nakamura, J. Yodoi, K. Sumikawa, T. Kondo, Glutaredoxin
exerts an antiapoptotic effect by regulating the redox state of Akt, J. Biol. Chem.
278 (2003) 50226–50233.
[49] M. Enoksson, A.P. Fernandes, S. Prast, C.H. Lillig, A. Holmgren, S. Orrenius,
Overexpression of glutaredoxin 2 attenuates apoptosis by preventing cytochrome
c release, Biochem. Biophys. Res. Commun. 327 (2005) 774–779.
[50] Z. Chen, C.C. Chua, Y.-S. Ho, R.C. Hamdy, B.H.L. Chua, Overexpression of Bcl-2
attenuates apoptosis and protects against myocardial I/R injury in transgenic
mice, Am. J. Physiol.: Heart Circ. Physiol. 280 (2001) H2313–H2320.
[51] A. Subramaniam, W.K. Jones, J. Gulick, S. Wert, J. Neumann, J. Robbins, Tissue-
speciﬁc regulation of theα-myosin heavy chain gene promoter in transgenic mice,
J. Biol. Chem. 266 (1991) 24613–24620.
[52] R. Hogan, F. Constantini, E. Lacy, Manipulating the mouse embryo: a la-
boratory manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, (1986)
90–203.
[53] P.S. Thomas, Hybridization of denatured RNA and small DNA fragments transferred
to nitrocellulose, Proc. Natl. Acad. Sci. U. S. A. 77 (1980) 5201–5205.
[54] C. Johansson, C.H. Lillig, A. Holmgren, Identiﬁcation of a new mammalian
glutaredoxin (thiotransferase), grx2, J. Biol. Chem. 279 (2004) 7537–7543.
[55] C. Little, R. Olinescu, K.G. Reid, P.J. O'Brien, Properties and regulation of glutathione
peroxidase, J. Biol. Chem. 245 (1970) 3632–3636.
[56] N. Hosova-Matsuda, K. Motohashi, H. Yoshimura, A. Nozaki, K. Inoue, M. Ohmori, T.
Hisabori, Anti-oxidative stress system in cyanobacteria. Signiﬁcance of type II
peroxiredoxin and the role of 1-Cys peroxiredoxin in Synechocystis sp. strain PCC
6803, J. Biol. Chem. 280 (2005) 840–846.
[57] Y.J. Kang, Z.-W. Zhou, G.-W. Wang, A. Buridi, J.B. Klein, Suppression by
metallothionein of doxorubicin-induced cardiomyocyte apoptosis through inhibi-
tion of p38 mitogen-activated protein kinases, J. Biol. Chem. 275 (2000)
13690–13698.
[58] A. Childs, S.L. Phaneuf, A.J. Dirks, T. Phillips, C. Leeuwenburgh, Doxorubicin
treatment in vivo causes cytochrome c release and cardiomyocyte apoptosis, as
well as increasedmitochondrial efﬁciency, superoxide dismutase activity, and Bcl-
2:Bax ratio, Cancer Res. 62 (2002) 4592–4598.
[59] R. Nithipongvanitch, W. Ittarat, J.M. Velez, R. Zhao, D.K. Clair St., T.D. Oberley,
Evidence for p53 as guardian of the cardiomyocyte mitochondrial genome
following acute adriamycin treatment, J. Histochem. Cytochem. 55 (2007)
629–639.
[60] X. Luo, I. Budihardjo, H. Zou, C. Slaughter, X. Wang, Bid, a Bcl2 interacting protein,
mediates cytochrome c release frommitochondria in response to activation of cell
surface death receptors, Cell 94 (1998) 481–490.
[61] L. Chaiswing, M.P. Cole, D.K. Clair St., W. Ittarat, L.I. Szweda, T.D. Oberley, Oxidative
damage precedes nitrative damage in adriamycin-induced cardiac mitochondrial
injury, Toxicol. Pathol. 32 (2004) 536–547.
[62] D.R. Green, G. Kroemer, The pathophysiology of mitochondrial cell death, Science
305 (2004) 626–629.
[63] G. Malik, N. Nogy, Y.-S. Ho, N. Maulik, D.K. Das, Role of glutaredoxin-1 in
cardioprotection: an insight with Glrx1 transgenic and knockout animals, J. Mol.
Cell. Cardiol. 44 (2008) 261–269.
[64] M.R. Fernando, J.M. Lechner, S. Löfgren, V.N. Gladyshev, M.F. Lou, Mitochondrial
thioltransferase (glutaredoxin 2) has GSH-dependent and thioredoxin reductase-
dependent peroxidase activities in vitro and in lens epithelial cells, FASEB J. 20
(2006) 2645–2647.
[65] P. Li, D. Nijhawan, I. Budihardjo, S.M. Srinivasula, M. Ahmad, E.S. Alnemri, X. Wang,
Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex
initiates an apoptotic protease cascade, Cell 91 (1997) 479–489.
[66] N.L. Reynaert, A. van der Vliet, A.S. Guala, T. McGovern, M. Hristova, C. Pantano, N.
H. Heintz, J. Heim, Y.-S. Ho, d.E. Matthews, E.F.M. Wouters, Y.M.W. Janseen-
Heininger, Dynamic redox control of NF-κB through glutaredoxin-regulated S-
glutathionylation of inhibitory κB kinase, Proc. Natl. Acad. Sci. U. S. A. 103 (2006)
10386–10391.
438 N.M. Diotte et al. / Biochimica et Biophysica Acta 1793 (2009) 427–438[67] S. Pan, B.C. Berk, Glutathiolation regulates tumor necrosis factor-α-induced
caspase-3 cleavage and apoptosis: key role for glutaredoxin in the death pathway,
Circ. Res. 100 (2007) 213–219.
[68] J. Wang, E. Tekle, H. Outrahim, J.J. Mieyal, E.R. Stadtman, P.B. Chock, Stable and
controllable RNA interference: investigating the physiological function of
glutathionylated actin, Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 5103–5106.[69] S. Qanungo, D.W. Starke, H.V. Pai, J.J. Mieyal, A.L. Nieminen, Glutathione
supplementation potentiates hypoxic apoptosis by S-glutathionylation of p65-
NFκB, J. Biol. Chem. 228 (2007) 18427–18436.
[70] H.C. Yen, T.D. Oberley, C.G. Gairola, L.I. Szweda, D.K. Clair St, Manganese superoxide
dismutase protects mitochondrial complex I against adriamycin-induced cardio-
myopathy in transgenic mice, Arch. Biochem. Biophys. 362 (1999) 59–66.
